PainScience.com Sensible advice for aches, pains & injuries
 
 

microblog

Topical NSAID risks much lower than oral 

Paul Ingraham ARCHIVEDMicroblog posts are archived and rarely updated. In contrast, most long-form articles on PainScience.com are updated regularly over the years.

NPR had a hit with this headline recently: “World's Most Popular Painkiller Raises Heart Attack Risk.” Sensational, and not wrong. Diclofenac in particular is an extremely popular drug — we’re talking oral here — and it is associated with serious cardiovascular risks: “There is increasing regulatory concern about diclofenac. … Diclofenac has no advantage in terms of gastrointestinal safety and it has a clear cardiovascular disadvantage” (McGettigan et al). But the difference between oral and topical is extremely important. Topical is not the same thing as swallowing at all. Volatren Gel (or Emulgel) is still a useful product. It has a proven benefit and much lower risks than oral. Scott Gavura wrote about this for ScienceBasedMedicine.org today:

The main advantage of topical NSAIDs is the reduced exposure of the rest of the body to the product, which reduces the side effect profile. Given the toxicity of NSAIDs is related in part to the dose, it follows that topical treatments should have a better toxicity profile. Consequently, the cardiovascular risks of topical diclofenac … should be negligible with the topical forms.

I’ve updated my article on this topic:

This is the MICROBLOG: small posts about interesting stuff that comes up while I’m updating & upgrading dozens of featured articles on PainScience.com. Follow along on Twitter, Facebook, or RSS. Sorry, no email subscription option at this time, but it’s in the works.